Hybrid Materials Advance Biomedicine
Time
3:00 PM, July 30, 2025 (Beijing)Contact Us
Email: bmehjournal@sciexplor.comSpeaker

Prof. Jianliang Shen
Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
Prof. Jianliang Shen received his Ph.D. degree from Sun Yat-Sen University in 2014 and completed his postdoctoral training at Houston Methodist Hospital Research Institute in 2017. Then, he started independent research work as a full professor at Wenzhou Medical University. His current research is focused on the hybrid biomaterial development of therapeutics and technologies to advance cancer immunotherapy and tissue engineering. His team's passion and motivation for research comes from the hope that they can bring good news to patients through the cross-disciplinary means of materials, chemistry and pharmacy. Prof. Shen has over 200 peer-reviewed publications in Nature Biotechnology, Chemical Society Reviews, Advanced Materials, Angewandte Chemie International Edition, Biomaterials and others. In addition, 42 papers were selected as “ESI highly cited papers”. His H-index records 63 (Google Scholar).
Host

Lei Zhang
College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China.
Dr. Lei Zhang is a professor of biomedical engineering at Zhejiang University. Before beginning this position in 2021, Dr. Zhang completed a three-year postdoctoral appointment in the Department of Materials Science and Engineering at the National University of Singapore. He received his PhD in Chemical Engineering from Zhejiang University in 2013. Dr. Zhang received the Hundred Talents Program in 2021. He is the author of more than 60 publications and 10 patents. His research interests include biocompatible/bio-sensitive organic conjugated polymers, as well as micro-/nano scale soft materials for flexible bioelectronic devices and bionic tissue engineering.